A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol

BACKGROUND: Small-cell lung cancer (SCLC) accounts for 12–15% of lung cancers and has a limited prognosis, with approximately one-third of SCLC patients having a poor performance status (PS). Patients with extensive-stage (ES) SCLC and a poor PS have a poor prognosis. For this population, overall su...

Descripción completa

Detalles Bibliográficos
Autores principales: Asao, Tetsuhiko, Watanabe, Satoshi, Tanaka, Takahiro, Morita, Satoshi, Kobayashi, Kunihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636802/
https://www.ncbi.nlm.nih.gov/pubmed/36333680
http://dx.doi.org/10.1186/s12885-022-10222-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636802/
https://www.ncbi.nlm.nih.gov/pubmed/36333680
http://dx.doi.org/10.1186/s12885-022-10222-1

Ejemplares similares